Biosimilars Market to Surpass US$ 9.5 Billion By 2022

New York, January 04, 2019: The scope of the report includes a detailed study of global and regional markets for Global Biosimilars Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India), Mylan, Inc.(U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and Merck KGaA (Germany). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

Browse the full report here:

The Global Biosimilars Market has been segmented as below:

The Global Biosimilars Market is Segmented on the lines of Product Analysis, Application Analysis and Regional Analysis. By Product Analysis this market is segmented on the basis of Recombinant Nonglycosylated Proteins, Recombinant Peptides and Recombinant Glycosylated Proteins.

By Application Analysis this market is segmented on the basis of Oncology, Blood Disorders, Growth Hormone Deficiency, Chronic and Autoimmune Diseases and Infectious Diseases. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

Biosimilar pills include erythropoietin, interferon, insulin, monoclonal antibodies (MABS), granulocyte colony stimulating elements and others. But, vaccines, plasma derived merchandise and their recombinant variations are excluded from the scope of this record. Furthermore, biologic capsules along with streptokinase and hyaluronidase are excluded from the observe due to the absence of right biosimilars recommendations. Patent expiry for reference biologics is placing the pace for the growth of biosimilars in this rather aggressive market. Recreating the patented protein structure for biosimilars is a key venture for regulators, as no two merchandise may be exactly the identical, which in addition complicates the regulatory procedure. Global biopharmaceutical regulators face numerous troubles bearing on the approval of biosimilars for numerous merchandise,

The Global Biosimilars Market is expected to exceed more than US$ 9.5 billion by 2022 and will grow at a CAGR of more than 26% in the given forecast period.

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Biosimilars Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Biosimilars Market data.
4) Assess your competitor’s refining portfolio and its evolution.

Market Research Engine has published a new report titled as “Biosimilars Market By Product Analysis (Recombinant Nonglycosylated Proteins, Recombinant Peptides, Recombinant Glycosylated Proteins); By Application Analysis (Oncology, Blood Disorders, Growth Hormone Deficiency, Chronic and Autoimmune Diseases, Infectious Diseases) and By Regional Analysis – Global Forecast by 2016 – 2022”

Request Sample Report:

Table of Contents


2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Biosimilars Market, By Type of Product

7 Biosimilars Market, By Type of Manufacturing

8 Biosimilars Market, By Application

9 Biosimilars Market, By Region

9.1 Introduction
9.2 North America Biosimilars Market
9.2.1 U.S.
9.2.2 Canada
9.3 Europe Biosimilars Market
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Biosimilars Market
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest of Asia (RoA)
9.5 Rest of the World (RoW) Biosimilars Market

10 Competitive Landscape

11 Company Profiles

11.1 Introduction

11.2 Pfizer Inc.

11.3 Sandoz International GmbH (A Division of Novartis International AG)

11.4 Teva Pharmaceutical Industries Ltd.

11.5 F. Hoffmann-La Roche Ltd.

11.6 Amgen Inc.

11.7 Biocon Ltd.

11.8 Dr. Reddy’s Laboratories

11.9 Celltrion Inc.

11.10 Mylan Inc.

11.11 Samsung Bioepis

Other Related Market Research Reports:

Biological Seed Treatment Market is Expected to Exceed US$ 1251.0 Million by 2023

Cell Counting Devices Market Share will Increase more than US$ 10 Billion By 2022

Cord Stem Cell Banking Market is Expected to Grow US$ 4 Billion By 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay


Phone: +1-855-984-1862

Country: United States


Leave a Reply

Your email address will not be published. Required fields are marked *